Subsidiary of Hunan Fangsheng Pharmaceutical (603998.SH) received the notice of acceptance of drug registration for YXQFZT granules.

Hunan Fangsheng Pharmaceutical (603998.SH) announced that in August 2024, its wholly-owned subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianmeng Pharmaceutical") completed the long-term toxicity test of the Blood-nourishing, Wind-expelling, Pain-relieving Granules (formerly known as Nuoli Tong Granules) and submitted an application for market approval to the National Medical Products Administration. On September 13, 2024, Jianmeng Pharmaceutical received the "Acceptance Notice" for the Blood-nourishing, Wind-expelling, Pain-relieving Granules. The Blood-nourishing, Wind-expelling, Pain-relieving Granules are based on the representative prescription "Shengxian Tang" of the famous modern Chinese medicine master Zhang Xichun. It can directly promote qi and blood to the head, improve cerebral blood supply insufficiency, and quickly relieve symptoms of headache and dizziness, and is used for the clinical treatment of frequent episodic tension-type headaches.